老年慢性病患者合作药物治疗管理模式的探索（英文）

我国正快速进入老龄化社会,多病共存、多重用药、机体功能下降是老年患者面临的严峻问题。实施慢性病的综合防控,加强老年常见病、慢性病的健康指导和综合干预,强化老年人的健康管理等措施势在必行。合作药物治疗管理(Collaborativedrugtherapymanagement,CDTM)是新医改形势下药学服务实践过程中应运而生的一种药物治疗管理模式,旨在扩大药师在医疗团队中的作用,提升医院医疗服务质量。CDTM虽然在老年慢性病管理中已取得初步成效,但由于医院配套设施、管理模式和药师能力的差异,在我国的推广受到了限制。本文通过对老年慢性病合作药物治疗管理模式的探索,为CDTM服务的进一步推广提供参考,同时为药师价值的展现,真实药学服务的实现奠定良好基础。     

灯盏细辛联合骨髓间充质干细胞移植对脑梗死的保护作用机制

背景：通过细胞移植重建损伤脑组织成为治疗脑梗死的新途径,骨髓间充质干细胞成为近年来细胞移植治疗领域的重要种子细胞之一。 目的：探讨灯盏细辛注射液联合骨髓间充质干细胞移植对急性脑梗死大鼠S100B蛋白及超氧化物歧化酶表达的影响。 方法：采用线栓法制作大鼠急性脑梗死模型,建模成功后将80只SD大鼠随机分为对照组、灯盏细辛组、骨髓间充质干细胞组及联合组。分别于治疗前后用酶联免疫法检测各组大鼠血清S100B蛋白水平,黄嘌呤氧化酶法检测各组大鼠血清超氧化物歧化酶的表达;通过NIHSS神经功能评分观察模型大鼠的神经行为学变化,通过TTC染色测定脑梗死体积。 结果与结论：在治疗后第3,7,14天,灯盏细辛组、骨髓间充质干细胞组的S100B蛋白水平明显低于对照组,但高于联合组,差异有显著性意义(P < 0.05);灯盏细辛组、骨髓间充质干细胞的超氧化物歧化酶表达水平明显高于对照组,低于联合组,差异有显著性意义(P < 0.05);治疗后第1,2,3周各组的NIHSS神经功能评分比较,联合组<灯盏细辛组及骨髓间充质干细胞组<对照组,差异有显著性意义(P < 0.05);在治疗后2周联合组的脑梗死体积明显小于灯盏细辛组及骨髓间充质干细胞组,灯盏细辛组及骨髓间充质干细胞组又明显小于对照组,差异有显著性意义(P < 0.05)。结果表明灯盏细辛注射液联合骨髓间充质干细胞移植能够抑制急性脑梗死大鼠S100B蛋白表达,提高超氧化物歧化酶活性,从而起到脑保护作用。 中国组织工程研究杂志出版内容重点：干细胞;骨髓干细胞;造血干细胞;脂肪干细胞;肿瘤干细胞;胚胎干细胞;脐带脐血干细胞;干细胞诱导;干细胞分化;组织工程     

丹参酮Ⅱ联合骨髓间充质干细胞移植促进脑梗死后的神经再生

BACKGROUND:Studies have shown that tanshinone II can improve microcirculation, dilate cerebral blood vessels, increase cerebral blood flow, reduce infarct size, and improve brain function after cerebral metabolic disorder. OBJECTIVE:To investigate the effect of tanshinone II combined with bone marrow mesenchymal stem cell transplantation on nerve regeneration following cerebral infarction in rats. METHODS:Rat models of acute cerebral infarction were prepared using the thread occlusion method and then given tanshinone II combined with bone marrow mesenchymal stem cell transplantation (combined group), bone marrow mesenchymal stem cell transplantation (cell transplantation group), and no treatment (model group), respectively. Neuromotor function was assessed using Longa scores. Expression of brain-derived neurotrophic factor gene around the infarction region was detected using RT-PCR. Cell apoptosis was detected using TUNEL. Immunohistochemistry staining was used to determine peri-cortex Nogo-A and NgR protein expression at the infarction region. RESULTS AND CONCLUSION:Longa scores, apoptotic index, and expression of Nogo-A and NgR proteins exhibited significant differences among three groups (P < 0.05) as follows: combined group < cell transplantation group < model group. Conversely, the expression of brain-derived neurotrophic factor gene was highest in the combined group successively followed by the cell transplantation group and model group (P < 0.05). These data show that tanshinone II combined with bone marrow mesenchymal stem cell transplantation accelerate the recovery of neurologic function and promote nerve regeneration after cerebral infarction by incresing mRNA expression of brain-derived neurotrophic factor.